Monday, March 3rd, 2008
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pfizer's chemotherapy agent, Camptosar(R) (Irinotecan Hydrochloride) Injection, 20 mg/mL. Shipment of this product, available in 40 mg/2 mL ...
Posted in Pharma Industry | No Comments »
Tuesday, February 19th, 2008
Biovail Corporation (NYSE: BVF) (TSX: BVF) announced that it has received a Notice of Compliance from the Therapeutic Products Directorate (TPD) for its supplemental New Drug Submission (sNDS) for a new indication for Wellbutrin® XL in Canada - the prevention of major depressive illness with an autumn-winter seasonal pattern.
The approval ...
Posted in Depression | No Comments »
Monday, February 18th, 2008
Diamyd Medical (NASDAQ:DMYDY)(STO:DIAMB) announced that it has received approval from the U.S. FDA to initiate a Phase I study in chronic pain using NP2, the company's first drug candidate in its Nerve Targeting Drug Delivery System (NTDDS) gene therapy platform.
NP2, developed by the company's U.S. subsidiary, Diamyd, Inc., in Pittsburgh, ...
Posted in Pain / Anesthetics | No Comments »
